Drug intelligence / Profile preview

TJ072

Development stage: Preclinical
Lead developer: Tuojie Biotech
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics

Overview

TJ072 is a preclinical-stage small interfering RNA (siRNA) therapeutic candidate being developed by Tuojie Biotech for the treatment of Alzheimer's disease. Utilizing RNA interference (RNAi) technology, TJ072 is designed to silence the expression of specific genes associated with the pathogenesis of Alzheimer's, such as those involved in the production of amyloid-beta or the aggregation of tau proteins. The program is currently in the preclinical candidate (PCC) stage and leverages Tuojie's proprietary delivery platforms for central nervous system applications.

Beyond the preview

Go deeper on TJ072.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TJ072.

Explore the full profile